

Performance Against Delivery Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure
1	17/LO/0249	220398	CO39385: Study of Atezolizumab + Enzalutamide vs Enzalutamide in mCRPC	Number Agreed	5	5	Date Agreed	31/05/2018	0	19/04/2018	0	Recruitment Finished
2	16/YH/0450	213782	20150288 - Blinatumomab in DLBCL	Number Agreed	1	1	Date Agreed	31/07/2018	0	27/04/2018	0	Recruitment Finished
3	14/SW/1085	161878	NCRN - 3159	Number Agreed	2	2	Date Agreed	17/03/2018	3	11/05/2018	3	Recruitment Finished
4	16/NE/0316	207651	Phase 1 Study CYP-001 for the Treatment of Acute Graft vs Host Disease	Number Agreed	2	2	Date Agreed	31/03/2018	2	23/05/2018	3	Recruitment Finished
5	15/LO/0710	177905	EMBARC:MDV3100-13 Phase3, Enzalutamide, nonmetastatic Prostate Cancer	Number Agreed	12	12	Date Agreed	31/12/2019	4	07/06/2018	4	Withdrawn by Sponsor
6	17/EM/0468	234972	A3921104 - Tofacitinib for treatment of Juvenile Idiopathic Arthritis	Number Agreed	1	1	Date Agreed	23/05/2018	0	20/06/2018	0	Recruitment Finished
7	15/EM/0300	180135	CANC 4488	Number Agreed	3	3	Date Agreed	30/06/2018	3	29/06/2018	3	Recruitment Finished
8	17/LO/1865	232414	Combination therapy with isatuximab in patients with multiple myeloma	Number Agreed	3	3	Date Agreed	31/03/2019	2	29/06/2018	2	Withdrawn by Sponsor
9	17/EM/0075	222172	High Energy High Protein Tube Feed Study	Number Agreed	1	1	Date Agreed	31/05/2018	1	31/05/2018	1	Recruitment Finished
10	16/EM/0194	194984	DERM 5311	Number Agreed	50	50	Date Agreed	29/06/2018	50	29/06/2018	50	Recruitment Finished
11	16/NW/0750	209722	A study to evaluate the acceptability of ZestiVits;	Number Agreed	4	4	Date Agreed	25/12/2017	2	16/07/2018	2	Recruitment Finished
12	13/NW/0697	137274	NCRN - 2352 PISARRO	Number Agreed	4	4	Date Agreed	31/12/2018	7	11/05/2018	7	Recruitment Finished
13	17/EE/0079	220827	CL010_168	Number Agreed	1	1	Date Agreed	31/12/2018	1	04/07/2018	1	Recruitment Finished
14	13/ES/0005	114717	NCRN525 (AZACITIDINE + BSC v PLACEBO + BSC) / AZA-MDS-003	Number Agreed	2	2	Date Agreed	31/05/2022	2	27/07/2018	2	Recruitment Finished
15	15/SW/0326	189007	ATLAS: JNJ56021927 (ARN509)	Number Agreed	10	10	Date Agreed	31/08/2018	13	30/07/2018	13	Recruitment Finished
16	16/LO/1222	191705	ATLANTIS Trial	Number Agreed	3	3	Date Agreed	31/07/2018	1	31/07/2018	1	Recruitment Finished
17	17/NE/0151	223815	SGI-110 vs Treatment Choice in Adults with Previously Treated AML	Number Agreed	3	3	Date Agreed	31/12/2018	4	14/09/2018	4	Recruitment Finished
18	17/SC/0055	219468	AIN457 Paed	Number Agreed	2	2	Date Agreed	07/11/2018	3	28/09/2018	3	Recruitment Finished
19	16/SC/0530	213306	Ketocal 2.5:1 LQ tolerance trial	Number Agreed	2	2	Date Agreed	30/09/2018	1	31/08/2018	1	Recruitment Finished
20	17/NE/0117	222778	Osteogenesis Imperfecta 3082/0003 Mereo BioPharma	Number Agreed	1	1	Date Agreed	30/12/2018	4	05/10/2018	4	Recruitment Finished
21	15/NE/0167	171524	MLN9708 in Multiple Myeloma Not Treated with Stem Cell transplantation - MILLENIUM	Number Agreed	4	4	Date Agreed	31/10/2018	3	08/10/2018	3	Recruitment Finished
22	16/LO/0581	194313	CANC 5246	Number Agreed	1	1	Date Agreed	15/10/2018	2	11/10/2018	2	Recruitment Finished
23	14/SC/1366	135118	NCRN - 3131: EPOCH TheraSphere in Metastatic Colorectal Carcinoma of the Liver (TS102)	Number Agreed	3	3	Date Agreed	30/09/2018	3	12/10/2018	3	Recruitment Finished
24	18/NW/0015	233850	CONSTANT	Number Agreed	50	50	Date Agreed	28/09/2018	62	31/10/2018	65	Recruitment Finished

Performance Against Delivery Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure
25	17/LO/1656	229212	CO39722 - Cobimetinib and atezolizumab v's pembrolizumab in melanoma	Number Agreed	3	3	Date Agreed	31/10/2018	2	07/11/2018	2	Recruitment Finished
26	18/EM/0027	235145	OPT-302 with ranibizumab for the treatment of wet AMD	Number Agreed	2	2	Date Agreed	30/11/2018	0	14/11/2018	0	Recruitment Finished
27	17/SW/0273	235783	SB11-G31-AMD-Comparison of efficacy&safety of SB11 and Lucentis in AMD	Number Agreed	5	5	Date Agreed	30/11/2018	5	14/11/2018	5	Recruitment Finished
28	18/LO/0683	239811	YO40245 (IMBrave150) - Atezolizumab & Bevacizumab Vs. Sorafenib in HCC	Number Agreed	4	4	Date Agreed	30/06/2021	0	08/12/2018	0	Recruitment Finished
29	15/NW/0009	160002	MCRN3127 (20130173)	Number Agreed	3	3	Date Agreed	31/01/2019	5	13/12/2018	5	Recruitment Finished
30	17/EM/0063	213979	Gilteritinib as Maintenance After Induction/Consolidation in CR1 AML (Astellas AML Maintenance Study)	Number Agreed	2	2	Date Agreed	30/11/2018	0	15/10/2018	0	Withdrawn by Host
31	18/LO/0126	239586	Phase 1 study of WVE-210201 in patients with DMD	Number Agreed	1	1	Date Agreed	21/12/2018	1	20/12/2018	1	Recruitment Finished
32	17/EM/0355	229043	SPIRIT 2	Number Agreed	4	4	Date Agreed	28/02/2019	0	28/02/2019	0	Withdrawn by Host
33	17/EE/0437	233853	AQUILA (54767414SMM3001)	Number Agreed	2	2	Date Agreed	13/12/2019	4	07/03/2019	4	Recruitment Finished
34	18/EM/0228	248988	Anti-viral effect of PC786 on RSV infection in HSCT recipients	Number Agreed	3	3	Date Agreed	11/03/2019	2	11/03/2019	2	Recruitment Finished
35	18/LO/0378	234232	PIONEER III	Number Agreed	12	12	Date Agreed	30/06/2019	6	15/03/2019	6	Recruitment Finished